Introduction
Discovery of unidentified drugs targeting signal transduction in cells is a principal strategy of pharmacotherapy for several diseases for which no cure exists. The largest transmembrane spanning receptor protein family in humans, G protein-coupled receptors (GPCRs), 1 are related to various physiological functions as a signal converter. 2, 3 Each GPCR protein is activated by extracellular stimuli of several types, thereby eliciting intracellular downstream signals. 4 Because of their fundamental roles in cells, GPCRs have been centrally positioned as a drug discovery target. 5 In practice, more than 40% of curative drugs currently under investigation are associated with GPCR signal transduction. 6 Various strategies to identify GPCR signals are applied to screen effective agents for GPCR from numerous chemical and clinical compound libraries. 7 Most such strategies specialize in high-throughput measurements that simply judge whether the unknown compound activates or inhibits the target GPCR signal or not. However, the reaction profile of GPCR to the specific ligand differs depending on the type of GPCR and the cellular environment. 8 Moreover, information related to the temporal variation of the GPCR signal is intrinsically important for the understanding of physiological drug effects. Therefore, timecourse analysis of GPCR in living cells is necessary for drug evaluation, although the data remain insufficient because of methodological difficulties.
In several approaches for measuring GPCR signals, split luciferase fragment complementation assays are notable for monitoring GPCR reactions in living cells. [9] [10] [11] The principle is based on genetically encoded luciferase fragment probes fused with GPCR and β-arrestin, which is a cytoplasmic protein interacting with GPCR for desensitization.
Because the interaction of GPCR with β-arrestin induces luciferase fragment complementation on the probes, the timing of interactions can be detected by bioluminescence. Therefore, the method has benefits for monitoring the temporal variation of GPCR activity in living cells. However, in high-throughput analysis, the measuring tool is generally limited by a luminescence plate reader with a photomultiplier, which makes it difficult to measure the multiple samples without a time lag.
This study examined a novel approach for the measurement of GPCR and β-arrestin interactions based on luciferase fragment complementation assays on a 96-well plate. To achieve simultaneous measurement of GPCR reactions in different ligand conditions, a highly sensitive luminescence imaging system was introduced as a detector. We measured the interaction of GPCR with β-arrestin in live cells with temporaldependent information.
Experimental

Mammalian expression vectors
Constructions of the cDNA encoding β2-adrenergic receptor (ADRB2) fused with C-terminal of Emerald Luciferase (ELuc) (394 to 542 amino acids) or β-arrestin2 fused with N-terminal of ELuc (1 to 415 amino acids) were established in our earlier report. For the design of therapeutic drugs, G protein coupled receptors (GPCRs) are notable targets. Many screening methods have been developed to identify effective agents for GPCR signaling. However, analyses of temporal variations of GPCR activity with specific ligands remain insufficient because of monitoring method limitations and difficulties. We previously developed a high-throughput bioluminescence measuring system to detect interactions of GPCR with β-arrestin based on split luciferase fragment complementation. By newly introducing a bioluminescence imaging technique into the system, we demonstrate a method for the temporal monitoring of GPCR-β-arrestin interactions in living cells during stimulation by different ligands.
High-throughput
Keywords GPCR, bioluminescence, luciferase, imaging, protein complementation assay Notes bovine serum (FBS), penicillin and streptomycin (P/S) at 37 C with 5% CO2. Transfection of plasmid DNAs into the cells was done using a reagent with Lipofectamine2000 (Invitrogen Corp.). The cells were screened with 0.8 mg/mL of Geneticin (G418) and 0.5 mg/mL of Zeocin in the medium. The resistant cells were isolated as stable expression cells.
Bioluminescence imaging assay with 96-well plate
HEK293 cells stably expressing the GPCR luminescence probes were cultured overnight on a 96-well plate with 100 μL/well of DMEM supplemented with 10% FBS and P/S at 37 C with 5% CO2. The medium was exchanged to 100 μL/well of Hank's balanced salt solution (HBSS) with 10% FBS and 10 mM (M = mol/L) of D-luciferin (Wako Pure Chemical Industries Ltd., Osaka, Japan). The cells were incubated on the stage of the imaging system at RT for 10 min. Some wells were treated preliminarily with propranolol (Wako Pure Chemical Industries Ltd.). Subsequently, isoproterenol (Wako Pure Chemical Industries Ltd.) was added directly to each well at different concentrations.
Bioluminescence imaging system
Bioluminescence images were obtained using a multi-functional in vivo imaging system (Miis; Molecular Devices Corp., Tokyo, Japan). An electron-multiplying CCD camera (EM-CCD, gain set to 800, iXon Ultra888; Andor Technology) was selected as a bioluminescence detector. Region dependent differences of luminescence count were kept within ±5%. Time-lapse bioluminescence images were acquired every 100 s, with 10 s exposure for each. The air temperature of the dark box was maintained at 24 C. All imaging processes and analyses of luminescence counts were conducted using software (Metamorph; Molecular Devices Corp.).
Results and Discussion
We established a bioluminescence system to detect the interaction of GPCR with β-arrestin by split luciferase fragment complementation (Fig. 1A) . 8, [10] [11] [12] For construction of a pair of probes, the C-terminal of fragment of Luciferase (LucC) is fused with GPCR. The N-terminal fragment of Luciferase (LucN) is then fused with an isoform of β-arrestin, β-arrestin2 (ARRB2). The HEK293 cells, which stably express the probe pair, are stimulated with an agonist in a dose-dependent manner. The luminescence on the 96-well plates is measured. These luminescence data are acquired at fixed time points by lysing cells. A conventional luminescence plate reader with a photomultiplier is used as a detector. Therefore, the standard protocol for the measurement of 96-well plates is performed while reading each well sample in turn. This procedure consequently generates severe time lags among the samples. Particularly, in split luciferase fragment complementation assays, longer exposure time is necessary to detect the signal because of weak luminescence. The time lag presents a risk of overlooking important information from the luminescence profile.
To overcome those shortcomings and difficulties, we introduced a luminescence imaging system that is ordinarily used for in vivo imaging to monitor the luminescence from living cells on a 96-well plate (Fig. 1B) . As a detector, the EM-CCD camera was set in this system. Such a camera has already been used in microscopic systems for single-cell luminescence imaging of GPCR-β-arrestin2 interactions, 10, 11 but no report in the literature describes its use for bioluminescence imaging of a 96-well plate. Using the EM-CCD camera with a wide-field lens, the entire luminescence image of the 96-well plate can be detected. The luminescence count of each well is extracted from the interest region of images. Accordingly, simultaneous imaging of multiple samples resolves the difficulty posed by the detection time lag.
To demonstrate the potential of this new strategy, dose-response analysis for GPCR activity based on split luciferase fragment complementation was performed using the imaging system. Because several types of luciferases are available, each having different luminescence intensity and wavelength, we needed to select the best one for real-time imaging that reflected the temporal information. The absolute luminescence intensity of luciferase is correlated directly with the detection time of the image. In addition, luciferase types using substrate D-luciferin show stable luminescence photon counts in sustained measurement. 13 Therefore, ELuc, which is an extremely bright luciferase using D-luciferin, was chosen for the imaging assay. 14 In an earlier study using ELuc, we demonstrated the potential of a split luciferase fragment complementation assay with GPCR protein, β2-adrenergic receptor (ADRB2), and β-arrestin2. 10 The luminescence counts increased concomitantly with the dose of the agonist, isoproterenol (Iso). From the report, HEK293 The N-terminal and C-terminal fragments of luciferase are fused respectively with β-arrestin2 (ARRB2) and GPCR. These probes were developed in an earlier study. 10 (B) Technical procedures of temporal bioluminescence imaging. Cells were incubated on a 96-well plate and were stimulated by GPCR ligand. Time-course variation of bioluminescence was detected continuously using an EM-CCD camera.
cells stably expressing the probe pair (ELucN-ARRB2 and ADRB2-ELucC) were cultured on a 96-well plate and were incubated with D-luciferin (Fig. 2) . Some wells were treated preliminarily with competitive inhibitor of Iso, propranolol (Prop), of which the concentration was increased stepwisely among rows of the well. Continuous luminescence images of the plate were taken using the EM-CCD camera after the stimulation of Iso (Fig. S1, Supporting Information) . The results demonstrated that 50 wells of samples in all were observed simultaneously for the variation of luminescence along the time, enabling acquisition of the image from each time point within 10 s. Therefore, in contrast to a conventional plate reader, this new imaging strategy shortens the total measuring time remarkably.
The simultaneous measurement of wells enables analyses of different samples in the same time course. To compare the temporal changing of ADRB2-β-arrestin2 interaction in different concentrations of Iso, the luminescence photon counts were calculated from each well region (Figs. 3A and S2A (Supporting Information)). Cells without stimulation or with 1 × 10 -8 M of Iso showed no increase in the counts during the observation. Over 1 × 10 -7 M of Iso induced a time-dependent increase of luminescence, which reached the peak within 50 min. The photon counts in the peak were found to be six-fold higher than those in the initial time points, which showed agreement with the result obtained using a conventional plate reader. 10 Additionally, the temporal patterns of luminescence appeared to change for each concentration of Iso. Inhibition for Iso in the presence of Prop was also analyzed from the results of temporal imaging (Figs. 3C and S2B (Supporting Information)). Over 1 × 10 -7 M of Prop inhibited the reaction of Iso remarkably. The inhibitory effects were not displayed at 1 × 10 -8 M and less. Unexpectedly, these concentration conditions caused higher luminescence intensities than those without Prop. Moreover, some time points showed acceleration of the luminescence. These results revealed that the effects of inhibitor for GPCR agonist varied dynamically according to the temporary concentration.
Conclusions
We demonstrated real-time bioluminescence imaging for the monitoring of GPCR activation in living cells. Using an EM-CCD camera, numerous cell samples were visualized simultaneously to assess the time-dependent variation of luminescence. These data suggest that the temporal patterns of GPCR activities are sensitive to the concentrations of GPCR agonist and the inhibitor. Time-course information from the imaging strategy is expected to be useful to evaluate the drug performance of GPCRs in living cells.
